GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascentage Pharma Group International (HKSE:06855) » Definitions » EV-to-EBITDA

Ascentage Pharma Group International (HKSE:06855) EV-to-EBITDA : -9.69 (As of Jun. 23, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Ascentage Pharma Group International EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Ascentage Pharma Group International's enterprise value is HK$8,584.6 Mil. Ascentage Pharma Group International's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-885.9 Mil. Therefore, Ascentage Pharma Group International's EV-to-EBITDA for today is -9.69.

The historical rank and industry rank for Ascentage Pharma Group International's EV-to-EBITDA or its related term are showing as below:

HKSE:06855' s EV-to-EBITDA Range Over the Past 10 Years
Min: -19.95   Med: -7.11   Max: -0.98
Current: -9.69

During the past 8 years, the highest EV-to-EBITDA of Ascentage Pharma Group International was -0.98. The lowest was -19.95. And the median was -7.11.

HKSE:06855's EV-to-EBITDA is ranked worse than
100% of 462 companies
in the Biotechnology industry
Industry Median: 8.545 vs HKSE:06855: -9.69

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-23), Ascentage Pharma Group International's stock price is HK$24.80. Ascentage Pharma Group International's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-3.588. Therefore, Ascentage Pharma Group International's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Ascentage Pharma Group International EV-to-EBITDA Historical Data

The historical data trend for Ascentage Pharma Group International's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascentage Pharma Group International EV-to-EBITDA Chart

Ascentage Pharma Group International Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial -3.34 -10.81 -6.90 -8.32 -10.73

Ascentage Pharma Group International Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.90 - -8.32 - -10.73

Competitive Comparison of Ascentage Pharma Group International's EV-to-EBITDA

For the Biotechnology subindustry, Ascentage Pharma Group International's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ascentage Pharma Group International's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascentage Pharma Group International's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Ascentage Pharma Group International's EV-to-EBITDA falls into.



Ascentage Pharma Group International EV-to-EBITDA Calculation

Ascentage Pharma Group International's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=8584.577/-885.9
=-9.69

Ascentage Pharma Group International's current Enterprise Value is HK$8,584.6 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ascentage Pharma Group International's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-885.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ascentage Pharma Group International  (HKSE:06855) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Ascentage Pharma Group International's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=24.80/-3.588
=At Loss

Ascentage Pharma Group International's share price for today is HK$24.80.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ascentage Pharma Group International's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-3.588.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Ascentage Pharma Group International EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Ascentage Pharma Group International's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Ascentage Pharma Group International (HKSE:06855) Business Description

Traded in Other Exchanges
Address
68 Xinqing Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215000
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The company's geographical segments include the United States and Mainland China.
Executives
Ascentage Limited
Gao Sharon Xia
Guo Edward Ming
Healthquest Pharma Limited
Li Ju-yun
Wang Shaomeng
Yang Dajun
Zhai Yifan
South Dakota Trust Company Llc 2301 Trustee
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Tian Yuan 2201 Interest of corporation controlled by you
Zhao Li 2202 Interest of your spouse
Xian Jin Zhi Zao Chan Ye Tou Zi Ji Jin You Xian He Huo 2201 Interest of corporation controlled by you
Xian Jin Zhi Zao Chan Ye Tou Zi You Xian Gong Si 2101 Beneficial owner
Guo Tou Chuang Xin Tou Zi Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you

Ascentage Pharma Group International (HKSE:06855) Headlines

No Headlines